Меню
Идёт набор NCT07131384

Interaction Between Inorganic Nitrate Supplementation and Metformin in Individuals With Prediabetes

Без фазы С лечением Males Females Sedentary Metformin

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Dietary Supplement: Inorganic Nitrate (Beetroot juice), Dietary supplement: Placebo (Nitrate-depleted beetroot juice).
Кому может быть актуально
Состояния в реестре: Males, Females, Sedentary, Metformin. Базовые параметры: 18 лет — 60 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

The Interaction Between Inorganic Nitrate Supplementation and Metformin on Exercise Capacity, Vascular Function, and Insulin Sensitivity in Individuals With Pre-Diabetes

Обзор

This study is examining whether short-term supplementation with inorganic nitrate, in the form of beetroot juice, can enhance blood vessel health, insulin sensitivity, and exercise capacity in individuals with prediabetes. We will be comparing the responses in individuals who are taking metformin to those who are naive to metformin. The results from this study may help identify non-pharmacological interventions in prediabetes.

Подробное описание

One in 10 Americans have diabetes, with \~ 95% having type 2 diabetes (T2D). Another 1 in 3 have prediabetes, with 70% developing T2D during their lifetimes. Exercise is the standard of care for T2D. However, responses to exercise are blunted in T2D, in part due to the widespread use of metformin, which may inhibit mitochondrial function. Alternative therapies, such as inorganic nitrate supplementation, may provide benefits without attenuating exercise responses.

Purpose: To examine inorganic nitrate supplementation on exercise tolerance, vascular function, and insulin sensitivity in subjects with PD (an ideal time to prevent progression to T2D) who are either taking or naïve to metformin pharmacotherapy.

This study willl recruit twenty-four individuals with PD (12 on, 12 metformin naïve) will participate in a double-blind cross-over design after either oral nitrate or placebo supplementation, including: 1) tests of vascular function (pulse wave velocity, flow mediated dilation, microvascular function with post-occlusive reactive hyperemia, local thermal heating, and skin ACh iontophoresis); 2) exercise testing to determine VO2peak and lactate threshold; 3) an oral glucose tolerance test; and 4) an exercise time trial to exhaustion.

Вмешательства

  • Пищевая добавка Dietary Supplement: Inorganic Nitrate (Beetroot juice)
    Participants will be supplemented with inorganic nitrate in the form of beetroot juice for 4 days (12.9 mmol of NO3/day), and their vascular health, insulin sensitivity, and exercise capacity will be measured post-supplementation. This is a randomized crossover design with 2 parallel groups (Group 1: Currently taking metformin, Group 2: Naive to metformin).
  • Пищевая добавка Dietary supplement: Placebo (Nitrate-depleted beetroot juice)
    Participants will be supplemented with nitrate-depleted beetroot juice for 4 days (\<0.01 mmol NO3/day), and their vascular health, insulin sensitivity, and exercise capacity will be measured post-supplementation. This is a randomized crossover design with 2 parallel groups (Group 1: Currently taking metformin, Group 2: Naive to metformin).

Первичные конечные точки

  • Vascular Endothelial Function (Pulse wave analysis and velocity [PWA/V]) [Срок оценки: 3 days following either active NO3 or placebo without nitrate (following 7-day washout).]
  • Vascular Endothelial Function (Flow-Mediated Dilation [FMD]) [Срок оценки: 3 days following either active NO3 or placebo without nitrate (following 7-day washout).]
  • Skin microvascular function using post-occlusive reactive hyperemia (PORH) [Срок оценки: 3 days following either active NO3 or placebo without nitrate (following 7-day washout)]
  • Skin microvascular function: Change in Skin Microvascular Dilation in Response to Local Thermal Heating [Срок оценки: 3 days following either active NO3 or placebo without nitrate (following 7-day washout).]
  • Skin microvascular function: Change in microvascular dilation in response to acetylcholine (ACh) [Срок оценки: 3 days following either active NO3 or placebo without nitrate (following 7-day washout)]
  • Oral Glucose Tolerance Test (OGTT) [Срок оценки: 3 days following either active NO3 or placebo without nitrate (following 7-day washout).]
  • Plasma Nitrate/Nitrite [Срок оценки: 4 days following either active NO3 or placebo without nitrate (following 7-day washout).]
  • Cardiorespiratory fitness [Срок оценки: 4 days following either active NO3 or placebo without nitrate (following 7 day washout).]
  • Exercise time trial to exhaustion (TTE) [Срок оценки: 4 days following either active NO3 or placebo without nitrate (following 7 day washout).]
  • Tissue oxygenation during exercise (near-infrared spectropscopy [NIRS] [Срок оценки: 4 days following either active NO3 or placebo without nitrate (following 7-day washout).]
Вторичные конечные точки (3)
  • Oral Microbiome [Срок оценки: 4 days following either active NO3 or placebo without nitrate (following 7-day washout).]
  • Biomarker Analyses: Concentration of Inflammatory markers in fasting blood plasma [Срок оценки: Sample collected 4 days post active NO3 juice/placebo and will be analyzed post study completion.]
  • Biomarker Analyses: Concentration of Oxidative stress markers in fasting blood plasma [Срок оценки: Sample collected 4 days post active NO3 juice/placebo and will be analyzed post study completion.]

Критерии участия

Критерии включения

  • Individuals who can communicate meaningfully with the investigator and can provide written consent.
  • Confirmed prediabetic individuals (ages 18-60 years old) (2-hour glucose of 140-199 mg/dL following OGTT test or HbA1c between 5.7-6.4% tested on two occasions within 6 months).
  • Taking metformin (stable dose for at least a week) or naïve to metformin
  • Sedentary (<1 day/week of structured exercise)
  • Be able to perform exercise on a cycle ergometer without assistance
  • Stable medication regimen for the last 6 months
  • If female, have a normal menstrual cycle

Критерии исключения

  • Estimated Glomerular filtration rate (GFR) ≤ 45
  • Body mass index ≥ 40 Kg/m2
  • HbA1c > 6.4%
  • Smokers within the last 5 years
  • Has experienced significant weight loss \~3 kg in the last three months or is taking any weight loss drugs
  • Current medical condition that prohibits exercising at high intensities
  • Currently on hormone replacement of any kind
  • History of myocardial infarction, cerebrovascular event, acute or unstable disease other than pre-diabetes or obesity
  • Currently taking any of the following medications (calcium channel blockers, statins, ACE or renin inhibitors, angiotensin receptor blockers, organic nitrates (e.g., nitroglycerine) or recent regular use of inorganic nitrates, alpha- or beta-blockers, diuretics, proton pump inhibitors, PDE-5 inhibitors (e.g.,: Cialis, Viagra), or xanthine oxidase inhibitors (e.g.,: Allopurinol))
  • Oral antibiotic use within the previous four weeks, including over-the-counter antibacterial mouthwash or a mouthwash containing chlorhexidine and unwilling to discontinue use
  • Oral cancer/severe oral disease
  • Uncontrolled hypertension (>140/90)
  • Had hysterectomy or oophorectomy
  • Fetuses, neonates, children, prisoners, cognitively impaired, non-English speaking participants

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Перекрёстный дизайн
Маскирование
Четверное слепое
Основная цель
Другое

Центры проведения

США · 1 центр
  • University of Virginia — Charlottesville

Идентификаторы

NCT: NCT07131384 · 302659

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗